PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decline in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 57,440 shares, a decline of 81.7% from the May 31st total of 313,070 shares. Approximately 10.1% of the company’s stock are sold short. Based on an average daily trading volume, of 4,968,100 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

PainReform Stock Up 13.5%

PRFX opened at $1.60 on Friday. PainReform has a 52 week low of $1.28 and a 52 week high of $17.95. The business’s 50 day moving average is $1.86 and its two-hundred day moving average is $2.83. The firm has a market cap of $1.39 million, a price-to-earnings ratio of -0.00 and a beta of 0.98.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) earnings per share for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.